Drug Profile

Opiranserin - Vivozon

Alternative Names: UNAFRA; VVZ-000149; VVZ-149

Latest Information Update: 26 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Vivozon
Class Benzamides; Non-opioid analgesics; Pyrans; Small molecules
Mechanism of Action Glycine plasma membrane transport protein inhibitors; Serotonin 5-HT2A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Registered Postoperative pain
Phase II Fibromyalgia; Myofascial pain
Discontinued Neuropathic pain; Pain; Pruritus

Most Recent Events

12 Dec 2024 Registered for Postoperative pain in South Korea (IV)
30 Nov 2023 Preregistration for Postoperative pain in South Korea (IV)
14 Mar 2023 Phase-II clinical trials in Fibromyalgia in South Korea (Topical, Gel) (Vivozon pipeline, March 2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com